Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Rademikibart /CBP-201 in Asthma. The expected timing is based on the latest available company guidance and may change.
Seabreeze STAT Asthma Ph2 Study. 5/13/25- Seabreeze STAT asthma initiated. 6/13/25- Supporting data presented at EAACI'25. Topline data in H1 2026. 11/12/25:- Presented new Ph2 asthma analyses at ERS 2025; Seabreeze STAT asthma recruitment ongoing; topline data H1 2026. 01/12/26:- New MOA data; Seabreeze STAT asthma recruitment ongoing; topline adjunct data now expected in Mid-2026. 03/31/26:- Seabreeze STAT asthma Ph2 recruitment ongoing; topline adjunct data expected mid-2026. 04/23/26:- DMC interim efficacy review completed; no sample size change. Seabreeze STAT topline data still expected Mid-2026. 05/12/26:- DMC review supports Seabreeze STAT asthma; enrollment ongoing; topline adjunct data expected mid-2026; plan post-topline FDA meeting. 06/17/26:- Seabreeze STAT Asthma enrollment completed; topline data expected in Early September 2026. FDA Ph3 meeting planned later 2026. 08/12/26:- Seabreeze STAT Asthma enrollment completed. Topline data will be reported in September 2026. FDA meeting will follow topline results.
Verification
Confirm timing and program details against the company announcement or filing.